病毒病mRNA疫苗的研究现状与展望

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

International Journal of Molecular and Cellular Medicine Pub Date : 2022-01-01 DOI:10.22088/IJMCM.BUMS.11.3.260

Vasavi Koppu, Deepa Poloju, Bhavani Puvvala, Kavitha Madineni, Shilpa Balaji, Chandana Muraleedharan Pillai Sheela, Sri Sai Charan Manchikanti, Satpathy Moon Moon

{"title":"病毒病mRNA疫苗的研究现状与展望","authors":"Vasavi Koppu, Deepa Poloju, Bhavani Puvvala, Kavitha Madineni, Shilpa Balaji, Chandana Muraleedharan Pillai Sheela, Sri Sai Charan Manchikanti, Satpathy Moon Moon","doi":"10.22088/IJMCM.BUMS.11.3.260","DOIUrl":null,"url":null,"abstract":"The mRNA vaccines replace our conventional vaccines (live-attenuated and inactivated vaccines) due to their high safety, efficacy, potency and low cost for their manufacturing. Since these many years, the use of these mRNA vaccines has been restricted as they are unstable and their low efficiency in in-vivo delivery. But now, these problems have been solved by recent technological advances. Many studies conducted in animal models and humans demonstrated the good results for the mRNA vaccines. This review provides you a detailed overview of mRNA viral vaccines and considers the current perspectives and future prospects.","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/19/ijmcm-11-260.PMC10440005.pdf","citationCount":"0","resultStr":"{\"title\":\"Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review.\",\"authors\":\"Vasavi Koppu, Deepa Poloju, Bhavani Puvvala, Kavitha Madineni, Shilpa Balaji, Chandana Muraleedharan Pillai Sheela, Sri Sai Charan Manchikanti, Satpathy Moon Moon\",\"doi\":\"10.22088/IJMCM.BUMS.11.3.260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The mRNA vaccines replace our conventional vaccines (live-attenuated and inactivated vaccines) due to their high safety, efficacy, potency and low cost for their manufacturing. Since these many years, the use of these mRNA vaccines has been restricted as they are unstable and their low efficiency in in-vivo delivery. But now, these problems have been solved by recent technological advances. Many studies conducted in animal models and humans demonstrated the good results for the mRNA vaccines. This review provides you a detailed overview of mRNA viral vaccines and considers the current perspectives and future prospects.\",\"PeriodicalId\":14152,\"journal\":{\"name\":\"International Journal of Molecular and Cellular Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/19/ijmcm-11-260.PMC10440005.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Molecular and Cellular Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22088/IJMCM.BUMS.11.3.260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular and Cellular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/IJMCM.BUMS.11.3.260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

mRNA疫苗因其高安全性、有效性、效力和低制造成本而取代了我们的传统疫苗(减毒活疫苗和灭活疫苗)。这些年来，这些mRNA疫苗的使用受到限制，因为它们不稳定且体内递送效率低。但是现在，这些问题已经被最近的技术进步解决了。在动物模型和人体中进行的许多研究表明mRNA疫苗具有良好的效果。这篇综述为您提供了mRNA病毒疫苗的详细概述，并考虑了目前的观点和未来的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review.

查看原文本刊更多论文

Current Perspectives and Future Prospects of mRNA Vaccines against Viral Diseases: A Brief Review.

The mRNA vaccines replace our conventional vaccines (live-attenuated and inactivated vaccines) due to their high safety, efficacy, potency and low cost for their manufacturing. Since these many years, the use of these mRNA vaccines has been restricted as they are unstable and their low efficiency in in-vivo delivery. But now, these problems have been solved by recent technological advances. Many studies conducted in animal models and humans demonstrated the good results for the mRNA vaccines. This review provides you a detailed overview of mRNA viral vaccines and considers the current perspectives and future prospects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Molecular and Cellular Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

3.60

自引率

0.00%

发文量

期刊介绍： The International Journal of Molecular and Cellular Medicine (IJMCM) is a peer-reviewed, quarterly publication of Cellular and Molecular Biology Research Center (CMBRC), Babol University of Medical Sciences, Babol, Iran. The journal covers all cellular & molecular biology and medicine disciplines such as the genetic basis of disease, biomarker discovery in diagnosis and treatment, genomics and proteomics, bioinformatics, computer applications in human biology, stem cells and tissue engineering, medical biotechnology, nanomedicine, cellular processes related to growth, death and survival, clinical biochemistry, molecular & cellular immunology, molecular and cellular aspects of infectious disease and cancer research. IJMCM is a free access journal. All open access articles published in IJMCM are distributed under the terms of the Creative Commons Attribution CC BY. The journal doesn''t have any submission and article processing charges (APCs).